Suppr超能文献

肿瘤内前部化疗:儿童晚期实体瘤的一种新型治疗方式。

Anterior intratumoural chemotherapy: a newer modality of treatment in advanced solid tumours in children.

作者信息

Gangopadhyay A N, Rajeev Rahi, Sharma S P, Upadhyaya Vijai D, Arya N C, Kumar Vijayendra, Gopal S C

机构信息

Department of Paediatric Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.

出版信息

Asian J Surg. 2008 Oct;31(4):225-9. doi: 10.1016/S1015-9584(08)60092-5.

Abstract

OBJECTIVE

Advanced and inoperable solid tumours in children have high mortality despite aggressive multimodal treatment. Intravenous chemotherapy is abandoned at times because of systemic toxicity. This study investigated intratumoural chemotherapy and compared it with intravenous chemotherapy.

METHODS

Forty children with advanced inoperable solid tumours (Wilms' tumour and neuroblastoma) were randomly allocated into two groups of 20. Group A was given intratumoural chemotherapy and group B was given intravenous chemotherapy. Both groups were compared for reduction in tumour size and volume, tumour resectability, histopathological changes and drug side effects.

RESULTS

Intratumoural chemotherapy was superior to intravenous chemotherapy in terms of reducing tumour size and volume (63% in group A vs. 22% in group B). The resectability was 70% in the intratumoural group compared with 40% in the intravenous group. The overall good histopathological response was 71% in group A as opposed to 0% in group B. Moreover, the incidence and severity of drug side effects and morbidity were less with intratumoural chemotherapy. Mortality was also low in group A (5%) compared to group B (20%).

CONCLUSION

Intratumoural chemotherapy can be offered as an effective and safe alternative treatment modality for advanced and inoperable Wilms' tumour and neuroblastoma.

摘要

目的

尽管采用了积极的多模式治疗,但儿童晚期及无法手术切除的实体瘤死亡率仍很高。有时会因全身毒性而放弃静脉化疗。本研究对瘤内化疗进行了调查,并将其与静脉化疗进行了比较。

方法

40例患有晚期无法手术切除实体瘤(肾母细胞瘤和神经母细胞瘤)的儿童被随机分为两组,每组20例。A组接受瘤内化疗,B组接受静脉化疗。比较两组肿瘤大小和体积的缩小情况、肿瘤可切除性、组织病理学变化及药物副作用。

结果

在缩小肿瘤大小和体积方面,瘤内化疗优于静脉化疗(A组为63%,B组为22%)。瘤内化疗组的可切除性为 70%,而静脉化疗组为40%。A组总体良好组织病理学反应率为71%,而B组为0%。此外,瘤内化疗的药物副作用发生率、严重程度及发病率较低。A组死亡率(5%)也低于B组(20%)。

结论

对于晚期及无法手术切除的肾母细胞瘤和神经母细胞瘤,瘤内化疗可作为一种有效且安全的替代治疗方式。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验